{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:45:10Z","timestamp":1773416710923,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and\/or critically ill patients can alter micafungin serum concentrations and the probability of target attainment. Although high doses of micafungin have been shown to be safe, clinical outcomes have not been widely evaluated. We conducted a single-center, retrospective observational study evaluating safety and clinical outcomes among adult patients treated with \u2265200 mg of micafungin for \u22653 days for proven IC from 1 September 2013 through 1 September 2021. Twenty-three unique encounters for 21 patients were evaluated. The median BMI and APACHE II scores were 37.1 (IQR 28.8\u201348.9) and 24 (IQR 17.7\u201331), respectively. The median average daily dose of micafungin was 300 mg (IQR 275\u2013400). Patients were treated with high-dose (HD) micafungin for the entirety of their echinocandin course in 15 encounters (65.2%). Transaminases remained stable, while a trend towards increased alkaline phosphatase was observed. A total of four deaths occurred (17.4%). Patients that died were predominantly young, Hispanic males who were obese and\/or critically ill. Future studies are needed to determine the necessity and appropriate placement of HD micafungin in obese and\/or critically ill patients.<\/jats:p>","DOI":"10.3390\/tropicalmed7020023","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T20:40:18Z","timestamp":1644180018000},"page":"23","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-0848","authenticated-orcid":false,"given":"Victoria C.","family":"Grant","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University Medical Center, Loma Linda, CA 92354, USA"},{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7931-7443","authenticated-orcid":false,"given":"Sasha","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University Medical Center, Loma Linda, CA 92354, USA"},{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-6408","authenticated-orcid":false,"given":"Jacinda C.","family":"Abdul-Mutakabbir","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"},{"name":"Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-2332","authenticated-orcid":false,"given":"Karen K.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University Medical Center, Loma Linda, CA 92354, USA"},{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"ref_1","unstructured":"Centers for Disease Control and Prevention (2021, December 27). Invasive Candidiasis Statistics, Available online: https:\/\/www.cdc.gov\/fungal\/diseases\/candidiasis\/invasive\/statistics.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/infdis\/jiaa502","article-title":"Invasive Candidiasis Species Distribution and Trends, United States, 2009\u20132017","volume":"223","author":"Ricotta","year":"2021","journal-title":"J. Infect. Dis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.00945-09","article-title":"Effect of antifungal therapy timing on mortality in cancer patients with candidemia","volume":"54","author":"Taur","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","unstructured":"(2021, December 27). Astellas Pharma US, Inc. Mycamine (micafungin) [package insert] U.S. Food and Drug Administration website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021506s009lbl.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","article-title":"Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients","volume":"56","author":"Martial","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","unstructured":"U.S. Census Bureau (2021, December 27). 2019. QuickFacts: San Bernardino County, California, Available online: https:\/\/www.census.gov\/quickfacts\/fact\/table\/sanbernardinocountycalifornia\/AFN120212?."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","unstructured":"Centers for Disease Control and Prevention (2021, December 27). Defining Adult Overweight & Obesity, Available online: https:\/\/www.cdc.gov\/obesity\/adult\/defining.html."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_17","first-page":"e449","article-title":"Burden of Candidemia in the United States, 2017","volume":"71","author":"Tsay","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3201\/eid2301.161198","article-title":"Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002\u20132012(1)","volume":"23","author":"Strollo","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40121-020-00285-7","article-title":"Impact of Obesity in Patients with Candida Bloodstream Infections: A Retrospective Cohort Study","volume":"9","author":"Barber","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"Kett","year":"2011","journal-title":"Crit. Care Med."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/2\/23\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:48Z","timestamp":1760134428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/2\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["tropicalmed7020023"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed7020023","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}